Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/9918
Full metadata record
DC FieldValueLanguage
dc.contributor.authorAckermann, Uween
dc.contributor.authorTochon-Danguy, Henri Jen
dc.contributor.authorNerrie, Maureenen
dc.contributor.authorNice, Edouard Cen
dc.contributor.authorSachinidis, John Ien
dc.contributor.authorScott, Andrew Men
dc.date.accessioned2015-05-15T23:12:12Z
dc.date.available2015-05-15T23:12:12Z
dc.date.issued2005-05-01en
dc.identifier.citationNuclear Medicine and Biology; 32(4): 323-8en
dc.identifier.govdoc15878501en
dc.identifier.otherPUBMEDen
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/9918en
dc.description.abstractFour analogues of AG957, a known inhibitor of the tyrosine kinase p210(bcr-abl), have been synthesized and tested for their growth inhibitory effect against the BCR/ABL-positive FDrv210C cells as well as the epidermal growth factor (EGF) receptor-positive Baf/ERX cells. All compounds that can undergo oxidation to the corresponding quinone demonstrated inhibition of FDrv210C cells and Baf/ERX cells. Compounds that cannot become oxidized showed significantly less inhibition of BCR/ABL- or EGF receptor-mediated cell proliferation. The (11)C-labeled compounds were prepared by labeling 4-aminobenzoic acid using [(11)C]CH(3)I, which afforded the corresponding (11)C-labeled methyl ester in excellent yields. Subsequent condensation of the amino group with an appropriately substituted hydroxy benzaldehyde formed the respective Schiff base. Reduction of this compound with NaBH(3)CN gave the (11)C-labeled inhibitors in an overall radiochemical yield of 17.3+/-2.1% (n=3; not decay corrected) and an average specific radioactivity of 40 GBq/micromol (1.1 Ci/micromol) at the end of synthesis. The total synthesis time from EOB including HPLC purification and formulation was 45 min.en
dc.language.isoenen
dc.subject.otherCarbon Radioisotopes.chemistry.diagnostic use.pharmacokineticsen
dc.subject.otherCell Line, Tumoren
dc.subject.otherCell Proliferation.drug effectsen
dc.subject.otherHumansen
dc.subject.otherIsotope Labeling.methodsen
dc.subject.otherLeukemia, Myelogenous, Chronic, BCR-ABL Positive.metabolism.pathology.radionuclide imagingen
dc.subject.otherPositron-Emission Tomography.methodsen
dc.subject.otherRadiopharmaceuticals.adverse effects.chemical synthesis.diagnostic use.pharmacokineticsen
dc.subject.otherTyrphostins.adverse effects.chemistry.diagnostic use.pharmacokineticsen
dc.titleSynthesis, 11C labeling and biological properties of derivatives of the tyrphostin AG957.en
dc.typeJournal Articleen
dc.identifier.journaltitleNuclear medicine and biologyen
dc.identifier.affiliationCentre for PET, Austin Health, Heidelberg, VIC 3084, Australiaen
dc.identifier.doi10.1016/j.nucmedbio.2005.02.006en
dc.description.pages323-8en
dc.relation.urlhttps://pubmed.ncbi.nlm.nih.gov/15878501en
dc.type.austinJournal Articleen
local.name.researcherAckermann, Uwe
item.languageiso639-1en-
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
item.openairetypeJournal Article-
crisitem.author.deptMolecular Imaging and Therapy-
crisitem.author.deptMolecular Imaging and Therapy-
crisitem.author.deptMolecular Imaging and Therapy-
crisitem.author.deptOlivia Newton-John Cancer Research Institute-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

56
checked on Dec 28, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.